Table 1. Patient clinical information.

	Patient 1	Patient 2	Patient 3
Age at diagnosis (years)	55	76	57
Gender	male	female	male
Ethnicity	Caucasian	Caucasian	Caucasian
Diagnosis	adenocarcinoma w/liver metastases	adenocarcinoma w/no metastasis	adenocarcinoma w/liver metastases
Tumor stage	IV	IIB	IV
Tumor grade	poorly differentiated	moderately differentiated	poorly differentiated
Tumor content	60%	50%	40–50%
Sequenced biopsy	liver metastasis	primary tumor	liver metastasis
Clinical status	Received treatmenta: deceased	Did not receive treatment: no recurrence after 24 months	Received treatmentb: deceased

^aClinical benefit with FOLFOX (folinic acid, fluorouracil, oxaliplatin) systemic therapy for 24 weeks with 98% maximal serum CA19-9 reduction and partial metabolic response by EORTC PET criteria.

^bTransient clinical benefit with FOLFOX systemic therapy for 10 weeks with maximal serum CA19-9 reduction of 36% and RECIST (Response Evaluation Criteria in Solid Tumors) reduction of 21% in sum of largest diameters.